Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · China

Breast Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Guangzhou 22 Beijing 19 Shanghai 8 Changsha 8 Hefei 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company8 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 Sun Yat-sen University4 Fujian Cancer Hospital3 Guangzhou Women and Children's Medical Center3
Site location
Guangzhou22 Beijing19 Shanghai8 Changsha8 Hefei7
All 59 locations
Target enrolment
to

Breast Neoplasms trials in China

66 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Guangzhou Women and Children's Medical Center
Not applicable
374
Guangzhou
2026-10-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
190
Hangzhou
2026-10
Recruiting
Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
NCT07698366Breast Neoplasms, Early Detection of Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
80,000
Kunshan, Nanjing
2026-09-20
Recruiting
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
216
Tianjin
2026-08-01
Not yet open
Fujian Cancer Hospital
Phase 2
35
Fuzhou, Quanzhou
2026-06-30
Recruiting
Fujian Cancer Hospital
Observational
100
Fuzhou, Quanzhou, Ningde, Sanming
2026-06-01
Recruiting
Eli Lilly and Company
Phase 2
600
2026-05-13
Active, closed
Peking Union Medical College Hospital
Observational
100
Beijing
2026-05-01
Recruiting
Peking Union Medical College Hospital
Observational
1,380
Beijing
2026-03-12
Recruiting
Fujian Cancer Hospital
Phase 2
2,000
Fuzhou, Chengdu
2026-01-21
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Recruiting
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
NCT07264998Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Abemaciclib, Abemaciclib-related Diarrhea
Hubei Cancer Hospital
Observational
60
Wuhan
2025-12-21
Recruiting
DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
NCT07263347Breast Neoplasms, Ischemia-Reperfusion Injury, Postoperative Complications, Wound Healing
Hubei Cancer Hospital
Observational
30
Wuhan
2025-12-20
Recruiting
BioNTech SE
Phase 3
558
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing
2025-10-30
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
340
Shanghai
2025-10-22
Not yet open
Yan Xue
Phase 4
40
Xi'an
2025-10-01
Recruiting
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Active, closed
The Third Affiliated Hospital of Harbin Medical University
Observational
6,000
Harbin
2025-05-13
Active, closed
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Observational
1,000
Hangzhou
2025-04-17
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
NCT07010939Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
FangYi
Observational
3,000
Beijing, Shenzhen, Taiyuan
2025-04-07
Recruiting
Xiangya Hospital of Central South University
Observational
1,000
Changsha
2025-03-11
Recruiting
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
NCT06567353Breast Neoplasms, Liver Neoplasms, Metastasis
Ruijin Hospital
Not applicable
10
Shanghai
2024-12-09
Recruiting
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Drugs[18F]F-RESCA-RB14·[18F]F-RESCA-RT4
RenJi Hospital
Phase 1/2
200
Shanghai
2024-09-21
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
Not yet open
Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
NCT06234150Breast Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction
The First Affiliated Hospital with Nanjing Medical University
Not applicable
90
Nanjing
2024-04-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
94
Guangzhou
2024-03
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
375
Guangzhou
2024-03
Recruiting
Second Affiliated Hospital of Soochow University
Not applicable
34
Suzhou
2024-02-01
Not yet open
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
wang shusen
Phase 2
116
Guangzhou
2023-09-20
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
170
Guangzhou
2023-08-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
196
Guangzhou
2023-08-01
Active, closed
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
NCT07149636Breast Neoplasms, Breast Self-Examination, Cancer Screening, Health Belief Model
Peking Union Medical College Hospital
Observational
3,000
Beijing
2023-06-01
Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
NCT05494502Breast Neoplasms, Mastectomy, Nerve Block, Dexmedetomidine
Peking University First Hospital
Not applicable
1,206
Beijing
2023-05-23
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
DrugSacituzumab Govitecan
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
566
Guangzhou
2022-11-23
Active, closed
Yin Ping
Not applicable
264
Shanghai
2022-10-20
Active, closed
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Active, closed
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Docetaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
102
Beijing
2022-06-21
Active, closed
Henan Cancer Hospital
Phase 2
120
Zhengzhou
2022-05-20
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Not yet open
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Active, closed
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Guangzhou Women and Children's Medical Center
Observational
150
Guangzhou
2021-10-01
Active, closed
Guangzhou Women and Children's Medical Center
Observational
127
Foshan, Guangzhou
2021-10-01
Recruiting
Shengjing Hospital
Phase 2
30
Shenyang
2021-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Fudan University
Phase 2
70
Shanghai
2021-03-01
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Sun Yat-sen University
Observational
700
Guangzhou
2020-01-01
Recruiting
Shengjing Hospital
Observational
500
Shenyang
2019-10-01
Recruiting
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect
Hunan Cancer Hospital
Observational
1,000
Changsha
2019-03-01
Active, closed
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
NCT03583580Breast Neoplasms, Neoplasm Recurrence, Local
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
537
Beijing
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
669
2014-07-22
Rows per page Showing 1–66 of 66
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 66 of those studies listing the condition Breast Neoplasms.

How many Breast Neoplasms trials are recruiting in China?

38 of the 66 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 20 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 66 studies
PhaseStudiesRecruitingShare
Observational18927.3%
Phase 314721.2%
Not applicable12818.2%
Phase 210615.2%
Phase 1649.1%
Phase 1/2436.1%
Phase 2/3111.5%
Phase 4101.5%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company84
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University77
Sun Yat-sen University43
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Fujian Cancer Hospital32
Guangzhou Women and Children's Medical Center30
Merck Sharp & Dohme LLC32
Peking Union Medical College Hospital31
Hubei Cancer Hospital22
Second Affiliated Hospital, Zhejiang University, School of Medicine21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.